CytoSorbents Corporation (CTSO) Stock Forecast and Price Target (2026)
Last updated November 2026
Short answer
There is no meaningful price-target consensus for CytoSorbents Corporation (CTSO): too few analysts publish a target on it for an average to mean anything. Thin coverage is normal for smaller and newer companies and says nothing about the business. What does exist is an earnings forecast. For the fiscal year ending Dec 2026, the one analyst publishing estimates on CTSO expects earnings of -$3.72 per share and revenue of $37.9 million (+2.1%). The full quarter and fiscal-year estimates are below, with the drivers and risks that decide whether they are met. Walnut is not an investment adviser.
Why CTSO has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. CTSO is one of them. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model.
At ~$4.39 the stock trades at roughly 0.4 times trailing sales, a level usually seen in medical device companies with serious balance sheet problems. Earnings ratios do not apply: trailing net loss is ~$16.9 million, much of it from non-cash currency swings and interest, and analysts expect a ~-$3.72 per-share loss for 2026. The November 2026 amendment cut the Avenue loan to ~$12.25 million and moved the maturity to July 2028, so the valuation now rests more on whether a business near cash breakeven with ~73-75% gross margins can grow toward the ~$44 million of 2027 revenue analysts forecast.
CTSO earnings and revenue forecast
For the fiscal year ending Dec 2026, the one analyst publishing estimates on CTSO expects earnings of -$3.72 per share and revenue of $37.9 million (+2.1%).
| Period | EPS estimate | EPS growth | Revenue estimate | Revenue growth |
|---|---|---|---|---|
Quarter ending Dec 2026 next quarter to report, 1 analyst | -$0.47 | n/a | $9.6 million | +4.3% |
Quarter ending Mar 2027 the quarter after, 1 analyst | $0.00 | n/a | $10.8 million | +22% |
Fiscal year ending Dec 2026 fiscal year next to report, 1 analyst | -$3.72 | n/a | $37.9 million | +2.1% |
Fiscal year ending Dec 2027 the fiscal year after, 2 analysts | $0.00 | n/a | $44 million $40.9 million to $47.1 million | +16% |
Consensus estimates for CTSO published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.
Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. CytoSorbents Corporation next reports on November 12, 2026, which is when these figures get tested against actual results.
Is there a 2030 forecast for CTSO?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering CTSO do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.
What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.
For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether CytoSorbents Corporation can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move CTSO from here
In short: the drivers cited most often are Operating cash flow at breakeven, Returning CytoSorb to growth, DrugSorb-ATR and the U.S. market. The risk cited most often against it is financing is still the largest risk, though the November 2026 deal changed its shape.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the CTSO is it a buy page.
Your questions about CytoSorbents Corporation
Ask Walnut's AI anything about CTSO and see how it fits what you own.
FAQ
What is the price target for CytoSorbents Corporation (CTSO)?
+
There is no meaningful consensus price target for CTSO, because too few analysts publish on it. Thin coverage is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Is there an analyst forecast for CTSO?
+
For earnings, yes; for the share price, not a meaningful one. For the fiscal year ending Dec 2026, the one analyst publishing estimates on CTSO expects earnings of -$3.72 per share and revenue of $37.9 million (+2.1%). Fewer analysts publish a price target on CTSO than publish earnings estimates, which is common for smaller and newer companies, and a lack of target coverage says nothing about the business itself.
What are analysts' earnings estimates for CytoSorbents Corporation (CTSO)?
+
For the fiscal year ending Dec 2026, the one analyst publishing estimates on CTSO expects earnings of -$3.72 per share and revenue of $37.9 million (+2.1%). For the fiscal year ending Dec 2027, the consensus is $0.00 per share. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.
When does CTSO report earnings next?
+
CytoSorbents Corporation's next earnings report is scheduled for November 12, 2026. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.
What could move CTSO?
+
The drivers and the risks are laid out on this page and in more depth on the CTSO "is it a buy" page. Without analyst estimates to anchor to, the useful framing is a set of scenarios.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.